Part I: Clinical Practice Guidelines for Children With Down Syndrome From Birth to 12 Years

References 

1. Centers for Disease Control and Prevention . Down syndrome prevalence at birth—United States, 1983-1990 . MMWR . 1994;43:617–622
2. In:  Cohen WI editors. Health care guidelines for individuals with Down syndrome . Down Syndrome Quarterly . 4: 1999;p. 1–15
3. Cooley WC . Nonconventional therapies for Down syndrome (A review and framework for decision making) . In:  Cohen WI ,  Nadel L ,  Madnick ME editor. Down syndrome (Visions for the 21st century) . New York: Wiley-Liss; 2002;
4. Committee on Genetics American Academy of Pediatrics . Health supervision guidelines for children with Down syndrome . Pediatrics . 2001;107:442–449
   • CrossRef
5. Committee on Infectious Diseases Committee on Fetus and Newborns American Academy of Pediatrics . Revised indications for the use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the prevention of respiratory syncytial virus infections . Pediatrics . 2003;112:1442–1446
   • CrossRef
6. Committee on Practice and Ambulatory Medicine American Academy of Pediatrics . Recommendations for preventive pediatric health care . Pediatrics . 2000;105:645–646
   • CrossRef
7. Committee on Sports Medicine and Fitness American Academy of Pediatrics . Atlantoaxial instability in Down syndrome (Subject review) . Pediatrics . 1995;96:151–153
   • MEDLINE
8. Joint Committee on Infant Hearing American Academy of Andrology American Academy of Pediatrics American Speech-Language-Hearing Association, & Directors of Speech and Hearing Programs in State Health and Welfare Agencies . Year 2000 Position Statement (Principles and guidelines for early hearing detection and intervention programs) . Pediatrics . 2000;106:798–817
   • CrossRef